Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669615 | 0.83 | HSD11B1 (0.34) | HSD11B1GPR119 | |
| Hydrochloric Acid SCHEMBL3716898 | 0.82 | HSD11B1 (0.33) | HSD11B1GPR119 | |
| SCHEMBL20878703 | 0.82 | NOTUM (0.35) | NOTUM | |
| SCHEMBL7655000 | 0.80 | HSD11B1 (0.36) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL23791454 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL15110040 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL7602702 | 0.78 | KDM4E (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL461807 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL1091053 | 0.78 | NOTUM (0.40) | HSD11B1NOTUMGPR119MAOAMAOB | |
| SCHEMBL4269099 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357546-B2 | Acceleration of diabetic wound healing | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-23 | — | — | US | disclosed |
| US-10253013-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-04-09 | — | — | US | disclosed |
| US-9951035-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951035-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170274053-A1 | ACCELERATION OF DIABETIC WOUND HEALING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170274053-A1 | ACCELERATION OF DIABETIC WOUND HEALING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-06 | — | — | US | disclosed |
| US-9604957-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253013-B2 | Selective matrix metalloproteinase inhibitors | MMP14, MMP9, MMP13 | HSD11B1 915/4885NOTUM 3181/4885GPR119 1265/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HSD11B1 2582/4885NOTUM 3121/4885GPR119 1314/4885 |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | HSD11B1 914/4885NOTUM 2228/4885GPR119 69/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | HSD11B1 2855/4885NOTUM 4195/4885GPR119 1348/4885 |
| US-20170274053-A1 | ACCELERATION OF DIABETIC WOUND HEALING | MMP8, MMP9, MMP1 | HSD11B1 1593/4885NOTUM 1758/4885GPR119 289/4885 |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | MMP14, MMP9, MMP13 | HSD11B1 915/4885NOTUM 3181/4885GPR119 1265/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | HSD11B1 364/4885NOTUM 391/4885GPR119 48/4885 |
| US-10357546-B2 | Acceleration of diabetic wound healing | MMP8, MMP9, MMP1 | HSD11B1 1593/4885NOTUM 1758/4885GPR119 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.